Clinical Report: Aspirin Administration for Secondary Prevention in ASCVD
Overview
This study investigates aspirin use for secondary prevention in adults with atherosclerotic cardiovascular disease (ASCVD) from 2015 to 2020. Despite negative perceptions surrounding aspirin for primary prevention, secondary prevention aspirin use remained stable during this period.
Background
Aspirin is widely recommended for secondary prevention of cardiovascular events, yet its use in primary prevention is contentious due to associated bleeding risks. Negative media and professional responses have led to a decline in primary prevention aspirin use, raising concerns about its impact on secondary prevention practices. Understanding aspirin use trends in secondary prevention is crucial for optimizing patient outcomes in ASCVD management.
Data Highlights
Characteristic
Value
Total Participants
1890
Aspirin Users
1427 (75.5%)
Never Users
277 (14.7%)
Aspirin Stoppers
186 (9.8%)
Median Age
70 years (IQR, 65-75)
Female Participants
719 (38.0%)
Male Participants
1171 (62.0%)
Key Findings
75.5% of participants with ASCVD were regular aspirin users.
Only 1.8% of aspirin stoppers cited negative messaging as the reason for discontinuation.
Participants who discussed aspirin with their physician were half as likely to stop using it.
No significant change in secondary prevention aspirin use was observed across the survey periods from 2015 to 2020.
Female participants were more likely to have never started aspirin therapy.
Clinical Implications
The stability of aspirin use for secondary prevention suggests that healthcare providers continue to support its use despite negative perceptions from primary prevention discussions. Engaging patients in conversations about aspirin therapy may reduce the likelihood of discontinuation, emphasizing the importance of physician-patient communication.
Conclusion
Aspirin remains a vital component of secondary prevention in ASCVD, with stable usage patterns observed despite external negative messaging. Continued education and dialogue between patients and healthcare providers are essential for maintaining appropriate aspirin therapy.
